functioned as the processing laboratory for a satellite site, the Florida Hospital Pepin Heart Institute, Tampa, Florida.
We are currently recruiting subjects into two additional cardiology clinical trials, with a third on the horizon. The NIH NHLBI's Cardiothoracic Surgical Trials Network (CTSN) Left Ventricular Assist Device (LVAD) Therapy Trial requires intramyocardial injection of allogeneic mesenchymal precursor cells (Mesoblast, Limited) during implantation of an LVAD, and involves receipt, storage, and cell preparation of the allogeneic mesenchymal cells. The second trial, Amorcyte, Inc., AMR-001, entails the intracoronary infusion of autologous bone marrow derived CD34+ selected cells in patients with acute myocardial infarction. Cells are harvested from the bone marrow and selected for CD34+ cells at an Amorcyte, Inc contracted facility, Progenitor Cell Therapy, LLC, using proprietary methods. The goals of both of these trials are to evaluate safety and the effect on cardiac function.
In addition, there is an imminent Baxter, Inc.-sponsored study involving intramyocardial delivery of G-CSF mobilized autologous CD34+ cells in patients with refractory angina pectoris and chronic myocardial ischemia, requiring subject apheresis with subsequent offsite centralized CD34+ selection and dose preparation.
APPROACH
Conducting cellular therapies for patients with cardiovascular diseases in our Stem Cell Laboratory provides exposure of the technologists to cutting edge therapies, but also requires enormous preparatory efforts and exquisite coordination among multiple disciplines. Generally, new clinical trials involve preliminary review of the established protocols to determine if our laboratory can provide the required services. We must determine our capability to perform these services within our existing workflow, staffing, budgetary and regulatory constraints. We must also evaluate our facility to determine if we have the capacity to accommodate the clinical trial requirements or if new technologies are needed, such as instrumentation, equipment, supplies and reagents. In situations when our Stem Cell Laboratory Directors are not involved in designing the clinical trial (especially in the case of industry-initiated studies), there is very little, if any, opportunity for protocol modifications. Therefore, each trial becomes a stand-alone effort requiring special attention outside the routine protocols of the laboratory.
Assessing the skillset needed by our staff required for each of these studies is essential. Often, protocols require processes that depart from routine stem cell laboratory protocols, which may necessitate additional validation and training (i.e. new instrument acquisition and surgical protocols). The need for specialized training must be considered and incorporated into the existing workload. Demanding, time-consuming cellular therapy manipulations may take an entire day, which are sometimes cumbersome for our single shift staffing. We attempt to manage this by training multiple staff members in all clinical trials. This enables greater flexibility within the laboratory. However, cross-training laboratory technologists require greater time commitment upfront. In many cases established protocol timelines require creative scheduling, not only for the Stem Cell Laboratory staff, but also for physicians, support staff, and internal/external testing laboratories.
Throughout, we must remain vigilant to avoid compromising services for our day-to-day BMT patient population.
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3 | P a g e Essential for any Stem Cell Laboratory is to ensure that required quality standards and regulations are met. In many cases, we are presented with already approved FDA IND clinical protocols, which were prepared without the benefit of cellular therapy personnel design, or familiarity with FACT (Foundation for the Accreditation of Cellular Therapy) accreditation standards. We must work to reconcile our internal regulatory and accreditation requirements with the (sometimes exacting) requirements of the clinical protocol. This experience has prompted our laboratory directors to make every attempt possible to participate in shaping new cell therapy protocol designs before IND application.
KNOWLEDGE GAINED
Our experiences have taught us that critical, strategic planning plays a key role. An established framework, with continuing process development, and key team member input, contributes to a more streamlined, positive outcome. Early on, we learned the importance of our cardiology colleagues involving us before agreement to participate in a specific trial. Our laboratory must quickly review the project protocol for participation. This translates into collaboration not only between the cardiologists and the Stem Cell Laboratory, but also within the hospital's BMT program, whose staff provides key functions such as collection and infusion, as well as other hospital departments and ancillary testing laboratories. As we participate in more and more trials, we are better equipped to anticipate and assess any bottlenecks, pitfalls, or protocol concerns. In addition, our laboratory directors are actively involved in multidisciplinary meetings with cardiologists, cardiothoracic surgeons and vascular surgeons so that we have opportunities to help shape the science and study protocol.
BENEFITS
Absorbing cardiac cellular therapy clinical trials into our laboratory work flow has been demanding, but has provided us with tremendous benefits, far exceeding the challenges. This experience has allowed us to establish our laboratory at the center of cell-based therapy at UF & Shands and parlay these new skills for other disciplines, such as neurology, endocrinology and ophthalmology. We have found that our newly acquired skillset is marketable within our own academic institution as well as with collaborations with outside institutions. Additionally, we now serve an important role in translational studies and as a reference for future clinical studies. We look forward to providing important contributions to the ever-evolving world of cellular therapy.
